Ultragenyx Pharmaceutical (RARE) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Schrodinger (SDGR) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 39.2% versus a loss of 50.9%. Over five years, SDGR leads with a -42.0% price change compared with -78.5% for RARE. Schrodinger is the larger company by market cap ($1.72 billion vs $1.68 billion), about 1.0 times the size.
Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -85.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RARE | SDGR |
|---|---|---|
| Share price | $16.48 | $22.93 |
| Market cap | $1.68B | $1.72B |
| 1-day change | -4.30% | -12.95% |
| YTD return | -28.35% | +28.24% |
| 1-year return | -50.94% | +39.22% |
| 5-year return | -78.45% | -42.01% |
| Forward P/E | 11.50 | — |
| EPS (TTM) | $-5.17 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $673.00M | $255.87M |
| Revenue growth (YoY) | +20.18% | +23.29% |
| Net income (latest FY) | $-575.00M | $-103.27M |
| Gross margin | — | 55.74% |
| Operating margin | -79.49% | -65.23% |
| Net margin | -85.44% | -40.36% |
| 52-week high | $39.89 | $34.00 |
| 52-week low | $12.73 | $10.95 |
| Distance from 52-week high | -58.69% | -32.56% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +50.49% | +46.40% |
| Average volume | 4.69M | 2.08M |
| Shares outstanding | 101.92M | 65.91M |
| Employees | 1,371 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed RARE by 90.2 percentage points over the past year.
- Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
RARE vs SDGR FAQ
Which is bigger, Ultragenyx Pharmaceutical or Schrodinger?
Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.68B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, RARE or SDGR?
SDGR returned +39.22% over the past 12 months, compared with -50.94% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Ultragenyx Pharmaceutical and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.